References
- Croucher CA, Lass A, Margara R, Winston RM. Predictive value of the results of a first in-vitro fertilization cycle on the outcome of subsequent cycles. Hum Reprod 1998; 13: 403–8.
- Hoveyda F, Engmann L, Steele J, Lopez BA, Barlow DH. Ovarian response in three consecutive in vitro fertilization cycles. Fertil Steril 2002; 77: 706–10.
- Kolibianakis E, Osmanagaoglu K, Camus M, Tournaye H, Van Steirteghem A, Devroey P. Effect of repeated assisted reproductive technology cycles on ovarian response. Fertil Steril 2002; 77: 967–70.
- Popovic-Todorovic B, Loft A, Lindhard A, Bangsboll S, Andersson AM, Andersen AN. A prospective study of predictive factors of ovarian response in ‘‘standard’’ IVF/ICSI patients treated with recombinant FSH. A suggestion for a recombinant FSH dosage normogram. Hum Reprod 2003; 18: 781–7.
- Popovic-Todorovic B, Loft A, Ejdrup Bredkjæer H, Bangsbøll S, Nielsen IK, Andersen AN. A prospective randomised clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a ‘‘standard’’ dose of 150 IU/day in ‘‘standard’’ patients undergoing IVF/ICSI treatment. Hum Reprod 2003; 18: 2275–82.
- Devroey P, Tournaye H, Van Steirteghem A, Hendrix P, Out HJ. The use of a 100 IU starting dose of recombinant follicle stimulating hormone (Puregon) in in-vitro fertilization. Hum Reprod 1998; 13: 565–6.
- Out HJ, Lindenberg S, Mikkelsen AL, Eldar-Geva T, Healy DL, Leader A et al. A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon) in women undergoing ovarian stimulation. Hum Reprod 1999; 14: 622–7.
- Out HJ, Braat DD, Lintsen BM, Gurgan T, Bukulmez O, Gokmen O et al. Increasing the daily dose of recombinant follicle stimulating hormone (Puregon) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation. Hum Reprod 2000; 15: 29–35.
- Out HJ, David I, Ron-El R, Friedler S, Shalev E, Geslevich J et al. A randomized, double-blind clinical trial using fixed daily doses of 100 or 200 IU of recombinant FSH in ICSI cycles. Hum Reprod 2001; 16: 1104–9.
- The Latin-American Puregon IVF Study Group. A doubleblind clinical trial comparing a fixed daily dose of 150 and 250 IU of recombinant follicle-stimulating hormone in women undergoing in vitro fertilization. Fertil Steril 2001; 76: 950–6.
- Land JA, Yarmolinskaya MI, Dumoulin JC, Evers JL. Highdose human menopausal gonadotropin stimulation in poor responders does not improve in vitro fertilization outcome. Fertil Steril 1996; 65: 961–5.
- Lashen H, Ledger W, Lopez BA, Evans B, Barlow D. Superovulation with a high gonadotropin dose for in vitro fertilization: is it effective? J Assist Reprod Genet 1998; 15: 438–43.